metoprolol succinate + immune checkpoint inhibitor + chemotherapy

This combination regimen consists of the selective beta-1 adrenergic receptor blocker metoprolol succinate administered in conjunction with standard neoadjuvant immunotherapy (immune checkpoint inhibitors) and chemotherapy. Developed by researchers at Nanfang Hospital, Southern Medical University, the regimen is being investigated for the treatment of locally advanced gastric cancer in patients with comorbid hypertension. The therapeutic rationale is based on the hypothesis that beta-blockers can modulate the tumor immune microenvironment and mitigate stress-induced immunosuppression, potentially enhancing the efficacy of immune checkpoint inhibitors and improving pathological response rates (such as Tumor Regression Grade) and long-term survival outcomes.

Other names

metoprolol succinate + neoadjuvant immunotherapy + chemotherapybeta-blockers combined with neoadjuvant immunotherapy and chemotherapy